Heart rhythm safety of two blood cancer drugs
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at whether two newer drugs for blood cancers, zanubrutinib and acalabrutinib, might increase the risk of an irregular heartbeat (atrial fibrillation). It aims to help doctors understand the heart risks of these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with a chronic B-cell blood cancer (like CLL or lymphoma).
- You have been or will be treated with zanubrutinib or acalabrutinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early signs of heart problems in people taking newer targeted blood cancer drugs called acalabrutinib or zanubrutinib. By using special blood tests, doctors hope to catch and manage heart issues before they become serious.
This study looks at whether certain blood cancer treatments increase the risk of an irregular heartbeat called atrial fibrillation. It may help doctors understand which patients need closer heart monitoring.
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This trial tests a different targeted drug, acalabrutinib, for people with CLL or SLL who developed heart problems (like atrial fibrillation) while taking ibrutinib. The goal is to see if acalabrutinib can control the cancer without causing the same heart side effects.
This study uses a small device placed under the skin to continuously monitor your heart rhythm while you take a BTK inhibitor (a type of targeted therapy for blood cancer). The goal is to catch irregular heartbeats early, which can be a side effect of these medicines.
Hear when a new BTK Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.